Nanostructured surfaces to target and kill circulating tumor cells while repelling leukocytes

Journal of Nanomaterials

Volumn 2012, Issue , 2012, Pages

  Mitchell, Michael J ^a   Castellanos, Carlos A ^a   King, Michael R ^a  

^a Cornell University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING KINETICS; BLOOD CELLS; CANCER CELLS; CIRCULATING TUMOR CELLS; DISTAL LOCATIONS; FUNCTIONALIZED; HALLOYSITE NANOTUBES; HUMAN NEUTROPHIL; LIPOSOMAL DOXORUBICIN; MCF-7 CELLS; MICROTUBE; NANOCARRIERS; NANOSTRUCTURED SURFACE; PATIENT PROGNOSIS; SELECTINS; TOXIC EFFECT;

CELL ADHESION; CELL DEATH; LIPOSOMES; NANOSTRUCTURED MATERIALS;

DIAGNOSIS;

EID: 84872766074     PISSN: 16874110     EISSN: 16874129     Source Type: Journal    
DOI: 10.1155/2012/831263     Document Type: Article

References (39)

1. Chaffer C. L., Weinberg R. A., A perspective on cancer cell metastasis. Science 2011 331 6024 1559 1564 2-s2.0-79953147370 10.1126/science.1203543
2. Hughes A. D., King M. R., Nanobiotechnology for the capture and manipulation of circulating tumor cells. WIREs Nanomedicine and Nanobiotechnology 2011 4 3 291 309
3. Coussens L. M., Werb Z., Inflammation and cancer. Nature 2002 420 6917 860 867 2-s2.0-0037180757 10.1038/nature01322 (Pubitemid 36019639)
4. Chambers A. F., Naumov G. N., Vantyghem S. A., Tuck A. B., Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Research 2000 2 6 400 407 2-s2.0-0034468235 10.1186/bcr86 (Pubitemid 32223636)
5. MacDonald I. C., Groom A. C., Chambers A. F., Cancer spread and micrometastasis development: quantitative approaches for in vivo models. BioEssays 2002 24 10 885 893 2-s2.0-0036794592 10.1002/bies.10156 (Pubitemid 35180844)
6. Young R. C., Ozols R. F., Myers C. E., The anthracycline antineoplastic drugs. The New England Journal of Medicine 1981 305 3 139 153 2-s2.0-0019501881 (Pubitemid 11073081)
7. Bouma J., Beijnen J. H., Bult A., Underberg W. J. M., Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties. Pharmaceutisch Weekblad 1986 8 3 109 133 2-s2.0-0022601925 (Pubitemid 16109043)
8. Osheroff N., Corbett A. H., Robinson M. J., Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Advances in Pharmacology 1994 29 105 126 2-s2.0-0028677807 10.1016/S1054-3589(08)61134-5
9. Reddy L. H., Drug delivery to tumours: recent strategies. Journal of Pharmacy and Pharmacology 2005 57 10 1231 1242 2-s2.0-27544446121 10.1211/jpp.57.10.0001 (Pubitemid 41545888)
10. Fritze A., Hens F., Kimpfler A., Schubert R., Peschka-Süss R., Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochimica et Biophysica Acta 2006 1758 10 1633 1640 2-s2.0-33749073801 10.1016/j.bbamem.2006.05.028 (Pubitemid 44466698)
11. Saad M., Garbuzenko O. B., Ber E., Chandna P., Khandare J. J., Pozharov V. P., Minko T., Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? Journal of Controlled Release 2008 130 2 107 114 2-s2.0-49749126336 10.1016/j.jconrel.2008.05.024
12. Herman E. H., Rahman A., Ferrans V. J., Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Research 1983 43 11 5427 5432 2-s2.0-0021029382 (Pubitemid 14230160)
13. Krishna R., McIntosh N., Riggs K. W., Mayer L. D., Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clinical Cancer Research 1999 5 10 2939 2947 2-s2.0-0032742140 (Pubitemid 29493973)
14. Gabizon A., Shmeeda H., Barenholz Y., Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clinical Pharmacokinetics 2003 42 5 419 436 2-s2.0-0037681850 10.2165/00003088-200342050- 00002 (Pubitemid 36649037)
15. Han H. D., Lee A., Hwang T., Song C. K., Seong H., Hyun J., Shin B. C., Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes. Journal of Controlled Release 2007 120 3 161 168 2-s2.0-34447296675 10.1016/j.jconrel.2007.03.020 (Pubitemid 47058634)
16. Čeh B., Winterhalter M., Frederik P. M., Vallner J. J., Lasic D. D., Stealth liposomes: from theory to product. Advanced Drug Delivery Reviews 1997 24 2-3 165 177 2-s2.0-0343632345 10.1016/S0169-409X(96)00456-5 (Pubitemid 27112632)
17. Allard W. J., Matera J., Miller M. C., Repollet M., Connelly M. C., Rao C., Tibbe A. G. J., Uhr J. W., Terstappen L. W. M. M., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical Cancer Research 2004 10 20 6897 6904 2-s2.0-6044259206 10.1158/1078-0432.CCR-04-0378 (Pubitemid 39383039)
18. Maheswaran S., Haber D. A., Circulating tumor cells: a window into cancer biology and metastasis. Current Opinion in Genetics and Development 2010 20 1 96 99 2-s2.0-75849140296 10.1016/j.gde.2009.12.002
19. Kansas G. S., Selectins and their ligands: current concepts and controversies. Blood 1996 88 9 3259 3287 2-s2.0-0029858031 (Pubitemid 26365560)
20. Li J., King M. R., Adhesion receptors as therapeutic targets for circulating tumor cells. Frontiers in Oncology 2012 2, article 79 10.3389/fonc.2012.00079
21. Läubli H., Borsig L., Selectins promote tumor metastasis. Seminars in Cancer Biology 2010 20 3 169 177 2-s2.0-77956614939 10.1016/j.semcancer.2010. 04.005
22. Krause T., Turner G. A., Are selectins involved in metastasis? Clinical and Experimental Metastasis 1999 17 3 183 192 2-s2.0-0032809670 10.1023/A:1006626500852 (Pubitemid 29360896)
23. Gout S., Tremblay P. L., Huot J., Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clinical and Experimental Metastasis 2008 25 4 335 344 2-s2.0-44449114208 10.1007/s10585-007-9096-4 (Pubitemid 351752950)
24. Springer T. A., Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994 76 2 301 314 2-s2.0-0027982876 10.1016/0092-8674(94)90337-9 (Pubitemid 24046692)
25. Mitchell M. J., King M. R., Shear-induced resistance to neutrophil activation via the formyl peptide receptor. Biophysical Journal 2012 102 8 1804 1814
26. Mitchell M. J., Chen C. S., Ponmudi V., Hughes A. D., King M. R., E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells. Journal of Controlled Release 2012 160 3 609 617 10.1016/j.jconrel.2012.02.018
27. Amselem S., Cohen R., Druckmann S., Gabizon A., Goren D., Abra R. M., Huang A., New R., Barenholz Y., Preparation and characterization of liposomal doxorubicin for human use. Journal of Liposome Research 1992 2 1 93 123 2-s2.0-0026736109
28. Haran G., Cohen R., Bar L. K., Barenholz Y., Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica et Biophysica Acta 1993 1151 2 201 215 2-s2.0-0027514941 10.1016/0005-2736(93)90105-9 (Pubitemid 23283973)
29. Lukyanov A. N., Elbayoumi T. A., Chakilam A. R., Torchilin V. P., Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. Journal of Controlled Release 2004 100 1 135 144 2-s2.0-7444236397 10.1016/j.jconrel.2004.08.007 (Pubitemid 39445991)
30. Myung J. H., Gajjar K. A., Pearson R. M., Launiere C. A., Eddington D. T., Hong S., Direct measurements on CD24-mediated rolling of human breast cancer MCF-7 cells on E-selectin. Analytical Chemistry 2011 83 3 1078 1083 2-s2.0-79952176839 10.1021/ac102901e
31. Huang Z., King M. R., An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation. Gene Therapy 2009 16 10 1271 1282 2-s2.0-70350142394 10.1038/gt.2009.76
32. Lee D., Schultz J. B., Knauf P. A., King M. R., Mechanical shedding of L-selectin from the neutrophil surface during rolling on sialyl lewis x under flow. The Journal of Biological Chemistry 2007 282 7 4812 4820 2-s2.0-33947540672 10.1074/jbc.M609994200 (Pubitemid 47100965)
33. Yin X., Rana K., Ponmudi V., King M. R., Knockdown of fucosyltransferase III disrupts the adhesion of circulating cancer cells to E-selectin without affecting hematopoietic cell adhesion. Carbohydrate Research 2010 345 16 2334 2342 2-s2.0-77958092075 10.1016/j.carres.2010.07.028
34. Kim M. B., Sarelius I. H., Distributions of wall shear stress in venular convergences of mouse cremaster muscle. Microcirculation 2003 10 2 167 178 2-s2.0-1542603668 10.1038/sj.mn.7800182 (Pubitemid 39004245)
35. Rana K., Reinhart-King C. A., King M. R., Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin. Molecular Pharmaceutics 2012 9 120702
36. Hughes A. D., King M. R., Use of naturally occurring halloysite nanotubes for enhanced capture of flowing cells. Langmuir 2010 26 14 12155 12164 10.1021/la101179y
37. Greene B. T., Hughes A. D., King M. R., Circulating tumor cells: the substrate of personalized medicine? Frontiers in Oncology 2012 2, article 69
38. Hughes A. D., Mattison J., Western L. T., Powderly J. D., Greene B. T., King M. R., Microtube device for selectin-mediated capture of viable circulating tumor cells from blood. Clinical Chemistry 2012 58 5 846 853 10.1373/clinchem.2011.176669
39. Begley C. G., Lopez A. F., Nicola N. A., Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 1986 68 1 162 166 2-s2.0-0022539985 (Pubitemid 16033624)